In a drug discovery career spanning more than two decades, Alex Lugovskoy has seen a lot of antibodies come and go. The vast majority of them work by inhibiting a cellular function. Lugovskoy, now the ...
With a $125 million series B financing round, Diagonal Therapeutics has made a vertical move to advance its first-in-class rare disease drug DIAG723. The Massachusetts-based biotech, which develops ...
Diagonal Therapeutics is taking shape, launching with $128 million and backed by the likes of BVF Partners, Atlas Venture and RA Capital to develop a pipeline of antibody agonists. The company will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback